Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Long OS with sipuleucel-T in mCRPC

Rana McKay • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Prostate Cancer Sipuleucel-T

Rana McKay, MD, University of California, San Diego, CA, discusses overall survival (OS) among medicare patients recieving sipuleucel-T versus oral treatment for metastatic castrate-resistant prostate cancer (mCRPC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Rana McKay

5:10
CheckMate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for RCC
Rana McKay • 17 Feb 2021
3:53
Homologous recombination repair pathway alterations in mHSPC
Rana McKay • 17 Feb 2021
5:41
Biomarker analysis of olaparib with or without cediranib in mCRPC
Rana McKay • 17 Feb 2021
11:22
Neoadjuvant androgen deprivation therapy in men with high-risk localized prostate cancer
Rana McKay • 28 May 2020

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals